Clinical Trial Update: SYS6010 Versus Docetaxel for Previously Treated EGFR Wild-type NSCLC: Phase Ⅲ [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial comparing SYS6010 to Docetaxel for previously treated EGFR wild-type non-small cell lung cancer; the study is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• SYS6010

Snippet

Sponsor: CSPC Megalith Biopharmaceutical Co.,Ltd. | Conditions: Non-Small Cell Lung Cancer | Phase 3 | Status: NOT_YET_RECRUITING